D. R. Burton

This study shows that potent antibody-dependent cellular cytotoxicity (ADCC) by a V2-specific antibody is insufficient to protect macaques against SIV challenge, but reduced viral loads were observed with a neutralization-sensitive SIV variant.

This study shows that germline-targeting SCIVs can activate and expand B cells expressing V2-apex bnAb-like precursors in rhesus macaques.

This study uses continuous immunogen delivery in rhesus macaques to focus antibody responses on the HIV fusion peptide, identifying key residues for vaccine design.

The paper identifies broadly neutralizing antibodies against SARS-CoV-2 that target conserved regions on the spike RBD, showing resistance to antigenic drift and suggesting potential vaccine targets.

This study identifies a new class of V2-directed cross-neutralizing antibodies targeting a cryptic epitope in occluded-open HIV and SIV Env trimers.

This paper introduces a pseudovirus system for deep mutational scanning of SARS-CoV-2 spike protein mutations, showing how they affect antibody neutralization and infection.

This study tracks antibody responses six months after Omicron BA.1 breakthrough infection and finds reduced neutralizing antibodies and memory B cells, with public clones dominating and predicting new sublineages.

Therapeutic monoclonal antibodies prevent death from YFV infection.

This paper develops aminoadamantane nitrate compounds that inhibit SARS-CoV-2 infection by S-nitrosylating ACE2 and blocking viral entry, showing efficacy in vitro and in a Syrian hamster model.

The paper identifies broadly neutralizing antibodies targeting the S2 region of betacoronavirus spikes that protect against SARS-CoV-1, SARS-CoV-2, and MERS-CoV.

This study shows that HIV-1 Vpu reduces nnAb recognition and ADCC resistance, with nnAb Fc-effector functions dependent on Env's open conformation.

This study identifies nAbs against SIVmac239, reveals structural features of its Env trimer, and shows passive transfer of nAbs protects macaques from infection.

This study shows that germinal center B cells can persist and continue to mutate for 29 weeks after a single immunization, leading to long-lasting antibody responses.

The paper identifies a YYDRxG motif in antibodies that broadly neutralize SARS-CoV-2 variants and related viruses, suggesting a conserved epitope targeting strategy.

This study isolates a panel of broadly neutralizing antibodies against SARS-like viruses from donors, showing effectiveness against multiple variants including Omicron.

This study shows that rhesus macaques can be immunized to produce broadly neutralizing antibodies against multiple SARS-related viruses, highlighting differences in B cell repertoires between humans and macaques.

The paper identifies 66 compounds that inhibit SARS-CoV-2 replication and 24 that synergize with remdesivir, suggesting potential oral drug repositioning candidates for COVID-19.

This study identifies a broadly neutralizing antibody that targets a conserved site on beta-coronavirus spike proteins and provides protection against SARS-CoV-2 infection.

The paper compares glycosylation patterns of recombinant SARS-CoV-2 spike proteins across labs with infectious virus S protein, finding conserved site-specific glycan maturation stalling linked to protein structure.

This study shows that off-target antibodies from HIV trimer vaccines cause trimer disassembly, exposing more off-target epitopes and driving further off-target immune responses.

The paper examines how mutations at E484 and K417 in SARS-CoV-2 variants affect neutralizing antibodies, showing reduced efficacy against certain antibody families but not others.

The paper uses cryoEM to analyze polyclonal antibody responses to HIV Env immunogens in rhesus macaques, revealing structural differences in antibody binding and immunogenicity of engineered mutations and glycan sites.

This study engineers an antibody, ADG-2, that broadly neutralizes SARS-CoV and SARS-CoV-2 in mice, offering protection against respiratory disease and viral replication.

The paper examines cross-reactive serum and memory B cell responses to SARS-CoV-2 and endemic coronaviruses, finding weak serum cross-reactivity but stronger memory B cell cross-reactivity.

The paper identifies IGHV3-53 as a common VH gene for SARS-CoV-2 neutralizing antibodies and determines its structural basis for binding the RBD.

The paper identifies broadly neutralizing antibodies against SARS-CoV-2 and related sarbecoviruses, highlighting a conserved epitope on the spike protein as a potential vaccine target.

This study shows that engineered HIV bnAb-expressing B cells can be expanded in vivo after vaccination, leading to durable bnAb memory and long-lived plasma cells.

This study determines the crystal structures of SPPV14 bound to BH3 peptides from Bax and Hrk, revealing an ionic interaction that mimics host Bcl-2:BH3 complexes to inhibit apoptosis.

This study shows that immunization with B41 and BG505 SOSIP trimer immunogens in rabbits induces distinct autologous neutralizing antibody lineages targeting overlapping glycan hole epitopes, but broadening reactivity remains challenging.

The paper compares antibody repertoires between a humanized rodent (OmniRat) and humans using high-throughput sequencing, identifying similarities and differences in diversity and recombination features.